Back

Pathogenicity assessment of a TSC2 c.2966+1G>A splice site variant in vaginal adenocarcinoma

Kenny, P. A.

2026-01-16 oncology
10.64898/2025.12.31.25343109 medRxiv
Show abstract

Clinical sequencing of a vaginal adenocarcinoma specimen yielded a reported TSC2 variant which was classified as splice-modulating loss-of-function, prompting consideration of a clinical trial for tumors with TSC2 loss. Literature review suggested that germline alterations affecting this particular exon are considered non-pathogenic, raising concern about the initial somatic variant interpretation. To resolve this ambiguity, raw data were provided by Tempus and an integrated DNA & RNA analysis allowed detailed characterization of the impact of this alteration on splicing. We confirm that this variant results in the complete exclusion of exon 26 from the transcript, however the exon 25-27 splice results in an in-frame transcript. Analysis of many additional wild-type tumor and normal tissue samples demonstrate that exon 26 is commonly spliced out of TSC2 transcripts, indicating that the transcript containing the exon 25-27 splice is highly unlikely to be pathogenic. This analysis did not support the classification of this variant as pathogenic and suggests that patients with such mutations should not be candidates for therapeutics designed for TSC2 dysfunction.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.